@article{524ca2220ea644c0865d0596dd49b97a,
title = "Activation of the Anti-Oxidative Stress Response Reactivates Latent HIV-1 Through the Mitochondrial Antiviral Signaling Protein Isoform MiniMAVS",
abstract = "The mitochondrial antiviral signaling protein (MAVS) is part of the cell{\textquoteright}s innate immune mechanism of defense. MAVS mRNA is bicistronic and can give rise to a full length-MAVS and a shorter isoform termed miniMAVS. In response to viral infections, viral RNA can be sensed by the cytosolic RNA sensors retinoic acid-inducible gene I (RIG-I) and/or melanoma differentiation-associated protein 5 (MDA5) and activate NF-κB through interaction with MAVS. MAVS can also sense cellular stress and activate an anti-oxidative stress (AOS) response through the activation of NF-κB. Because NF-κB is a main cellular transcription factor for HIV-1, we wanted to address what role MAVS plays in HIV-1 reactivation from latency in CD4 T cells. Our results indicate that RIG-I agonists required full length-MAVS whereas the AOS response induced by Dynasore through its catechol group can reactivate latent HIV-1 in a MAVS dependent manner through miniMAVS isoform. Furthermore, we uncover that PKC agonists, a class of latency-reversing agents, induce an AOS response in CD4 T cells and require miniMAVS to fully reactivate latent HIV-1. Our results indicate that the AOS response, through miniMAVS, can induce HIV-1 transcription in response to cellular stress and targeting this pathway adds to the repertoire of approaches to reactivate latent HIV-1 in {\textquoteleft}shock-and-kill{\textquoteright} strategies.",
keywords = "Dynasore, HIV-1, MAVS, anti-oxidative stress response, latency, latency-reversal agents, reactive oxygen species, shock and kill",
author = "Indra Sarabia and Novis, {Camille L.} and Macedo, {Amanda B.} and Hiroshi Takata and Racheal Nell and Kakazu, {Juyeon C.} and Furler, {Robert L.} and Binita Shakya and Schubert, {Heidi L.} and Hill, {Christopher P.} and DePaula-Silva, {Ana Beatriz} and Spivak, {Adam M.} and Lydie Trautmann and Vicente Planelles and Alberto Bosque",
note = "Funding Information: This work was partially supported by the National Institute of Health grants R21-AI106438 and R01-AI124722 to AB, R01-AI143567, R33AI122377 and R21-AI123035 to VP, cooperative agreement W81XWH-07-2-0067 between the Henry M. Jackson Foundation and the U.S. Department of Defense to LT, and P50AI150464 to CH and HS. IS was supported with a fellowship by the National Institutes of Health under the Ruth L. Kirschstein National Research Service Award NIH F31 AI147814. We thank Dr. Ryan O{\textquoteright}Connell (University of Utah) for the lentiCRISPRv2 plasmid, Dr. Jonathan Karn (Case Western Reserve University) for the 2D10 cells, Dr. Eric Verdin (University of California San Francisco) for the J-Lat 10.6 and 6.3 cell clones, Dr. Warner Greene (Gladstone Institute) for the 5A8 cells. This work was supported by the University of Utah Flow Cytometry Facility in addition to the National Cancer Institute through Award Number 5P30CA042014-24. This research has been facilitated by the services and resources provided by the District of Columbia Center for AIDS Research, an NIH funded program (AI117970), which is supported by the following NIH Co-Funding and Participating Institutes and Centers: NIAID, NCI, NICHD, NHLBI, NIDA, NIMH, NIA, FIC, NIGMS, NIDDK, and OAR. Publisher Copyright: {\textcopyright} Copyright {\textcopyright} 2021 Sarabia, Novis, Macedo, Takata, Nell, Kakazu, Furler, Shakya, Schubert, Hill, DePaula-Silva, Spivak, Trautmann, Planelles and Bosque.",
year = "2021",
month = jun,
day = "14",
doi = "10.3389/fimmu.2021.682182",
language = "English (US)",
volume = "12",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",
}